Skip to main content
Industry News
Glaxo's Nucala approved for hypereosinophilic syndrome

GlaxoSmithKline's biologic Nucala, or mepolizumab, has been approved by the FDA as a treatment for a subset of patients with hypereosinophilic syndrome who are at least 12 years old. The IL-5 antagonist has previously received FDA approval as a treatment for pediatric patients with severe asthma, eosinophilic asthma, and eosinophilic granulomatosis with polyangiitis.

Full Story: